MedTrace Logo

Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies

NCT01364051 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2026-04-13

No results posted yet for this study

Summary

This phase I trial studies the side effects and best dose of cediranib maleate and selumetinib sulfate in treating patients with solid malignancies. Cediranib maleate and selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may also stop the growth of tumor cells by blocking blood flow to the tumor.

Conditions

  • Metastatic Melanoma
  • Refractory Malignant Solid Neoplasm
  • Stage IV Cutaneous Melanoma AJCC v6 and v7
  • Unresectable Malignant Solid Neoplasm

Interventions

DRUG

Cediranib

Given PO

DRUG

Cediranib Maleate

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Selumetinib

Given PO

DRUG

Selumetinib Sulfate

Given PO

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Brian A Costello · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-25
Primary Completion
2019-06-06
Completion
2027-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01364051 on ClinicalTrials.gov